Detalhe da pesquisa
1.
Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials.
Ann Rheum Dis
; 81(2): 206-213, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34615638
2.
Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY.
Rheumatology (Oxford)
; 60(7): 3209-3221, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33313898
3.
Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate.
Ann Rheum Dis
; 77(11): 1566-1572, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30076156
4.
Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
Arthritis Res Ther
; 24(1): 155, 2022 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35751108
5.
Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
Arthritis Res Ther
; 24(1): 248, 2022 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36329507